Global Omega Balance Open Letter
A Global Call to Action for Human Health
Today, our world faces a preventable crisis rooted in a silent but widespread nutritional imbalance — a severe disruption in Omega-3 and Omega-6 fatty acid ratios. This imbalance affects cellular function, immunity, inflammation, neurodevelopment, and overall biological resilience. Scientists, clinicians, biochemists, metabolic researchers, and medical practitioners across the globe have independently raised concern about this issue, yet it remains insufficiently addressed at national and international policy levels.
The Wellness Alliance: Truth in Health Association 501(c)(3) is coordinating this Open Letter to bring together global experts and concerned citizens in unified scientific voice. This statement will be formally delivered to:
- The U.S. Department of Health & Human Services (HHS)
- Secretary Robert F. Kennedy Jr.
- President Donald J. Trump and senior transition advisors
The purpose of this initiative is to request formal acknowledgment, scientific review, and coordinated policy action regarding the essential fatty acid composition of modern diets and its profound impact on global health.
Why This Matters
For decades, populations worldwide have drifted into a state of nutritional malregulation created by:
- high consumption of omega-6–rich processed oils,
- insufficient intake of long-chain omega-3 fatty acids, and
- dramatic changes in agricultural and food production systems.
These shifts can contribute to:
- Compromised immune function
- Higher systemic inflammation
- Cardiometabolic dysfunction
- Altered neurodevelopmental trajectories
- Reduced resilience and repair
- Increased vulnerability to chronic disease and infection
Although abundant scientific evidence exists across lipid biology, neuroscience, developmental physiology, and metabolic research, public policy guidance has not kept pace with the science.
This global Open Letter calls for evidence-based leadership to reassess essential fatty acid exposures across populations and align food systems with human biological needs.
Add Your Voice
Professionals, scientists, clinicians, academics, policymakers, and members of the public are invited to sign.
Your signature will be included in the official submission and public signatory list.
Please review the scientific statement below and add your name using the form provided.
GLOBAL SCIENTIFIC STATEMENT ON ESSENTIAL FATTY ACIDS, LIPID COMPOSITION, AND HUMAN HEALTH
To Heads of State, Ministers of Health, Directors of International and Regional Health Agencies, and Leaders of Global Food and Agriculture Systems:
We, the undersigned scientists and clinicians working in lipid biology, nutrition, metabolism, developmental neuroscience, resolution pharmacology, and the endocannabinoid system, write to draw your attention to a critical but addressable aspect of modern human nutrition: the altered intake and biological handling of essential fatty acids, particularly omega-3 and omega-6 polyunsaturated fatty acids (PUFAs), and their impact on human physiology across the life course.
Our aim is not to declare a simple “villain” nutrient, but to underscore that current dietary patterns and food systems have created a biochemical milieu without historical precedent, and that this milieu has profound implications for inflammation, neurodevelopment, cardiometabolic disease, and healthy aging. We believe this warrants coordinated national and international assessment, guidance, and education.
Essential Fatty Acids: What Is Not in Dispute
There is broad scientific agreement that:
- Omega-3 and omega-6 fatty acids are both essential.
They are required for membrane structure, cell signaling, neurodevelopment, immune function, and the production of a wide range of lipid mediators, including eicosanoids and specialized pro-resolving mediators (SPMs). - Individual fatty acids are not interchangeable.
Linoleic acid (LA), arachidonic acid (ARA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) each have distinct structures, metabolic fates, and biological effects. Treating “omega-6” or “omega-3” as homogeneous categories can obscure important differences in risk and benefit. - Requirements change across the lifespan.
For example, arachidonic acid and DHA are especially critical during fetal development and early childhood for proper brain, eye, and immune development, and inadequacy in these windows can have lifelong consequences. - Modern dietary patterns differ substantially from those in which human physiology evolved.
Agricultural practices, animal feed composition, food processing, and global supply chains have altered the fatty acid composition of both plant oils and animal-source foods, often increasing certain omega-6 species and reducing long-chain omega-3s. - Many human populations studied today are not nutritionally “ideal.”
Evidence suggests that current reference ranges may reflect populations with altered fatty-acid profiles, micronutrient insufficiencies, and chronic low-grade inflammation.
Why This Matters for Public Health and National Capacity
Essential fatty acids participate in:
- regulation of inflammation and its resolution,
- brain development, cognition, and mental health,
- cardiovascular and metabolic homeostasis,
- immune competence and host defense,
- the function of systems such as the endocannabinoid system.
When intake patterns and tissue composition of these fatty acids are substantially shifted— whether by high LA intake, low EPA/DHA intake, altered animal feeds, or ultra-processed dietary patterns—there is concern that inflammatory responses, neurodevelopmental trajectories, and cardiometabolic risk profiles may be negatively affected.
These issues affect educational attainment, workforce productivity, and long-term health expenditure trajectories of every nation.
Areas of Active Scientific Discussion
The undersigned acknowledge ongoing scientific debate, including:
- Individual omega-6 fatty acids behave differently and should not be grouped into a single category.
- The meaning and usefulness of a single “omega-6:omega-3 ratio” without specifying fatty acids, tissues, or context.
- Age-dependent requirements and windows of vulnerability (pregnancy, early childhood, aging).
These open questions strengthen rather than weaken the case for coordinated action. They highlight how much is at stake and how much clarity is still needed.
What We Urge Governments and International Bodies to Do
- Establish National Essential Fatty Acid Committees or Task Forces
Mandated to review current intakes, tissue levels, and health outcomes related to key fatty acids, with representation from lipid biochemistry, clinical nutrition, pediatrics, neurology, psychiatry, cardiometabolism, immunology, and public health. - Conduct Comprehensive National and Regional Assessments
Map dietary intakes; assess biomarkers; evaluate associations with cardiovascular disease, diabetes, obesity, autoimmune and inflammatory conditions, neurodevelopmental and neurodegenerative disorders, and mental health. - Develop Evidence-Based Guidance for Food Systems and Agriculture
Review how agricultural policies, animal feeds, and food processing affect population exposures to specific fatty acids; consider improvements for long-chain omega-3 intake. - Integrate Essential Fatty Acids into Health Professional Education
Ensure medical, nursing, dietetic, and public-health training includes robust coverage of fatty acids and their physiological roles. - Support Research on Individual Fatty Acids and Lifespan Needs
Fund mechanistic and clinical research; clarify age-specific requirements; improve methods for tissue-level lipid assessment. - Collaborate Through International Platforms
Utilize WHO, FAO, UNICEF, and other agencies to harmonize data and develop guidance.
A Call for Coordinated, Evidence-Based Leadership
This statement is not a call for simplistic dietary prescriptions or for blaming any single nutrient. It is a call for recognition that modern fatty acid patterns differ substantially from those that shaped human physiology; for transparent assessment of their relationship to disease burden and human potential; and for leadership in aligning agriculture, food policy, and health systems with biological needs.
The potential gains in health, cognition, resilience, and national prosperity could be generational.
Respectfully,
Charles “Chip” Paul
ECS Theorist & Public Health Advocate
Convenor, Global Scientific Statement on Essential Fatty Acids,
Lipid Composition & Human Health
Scientific Signatories
Prof. Philip C. Calder, PhD, RNutr, FSB, FAfN
Professor of Nutritional Immunology
Faculty of Medicine
University of Southampton
Southampton, United Kingdom
Hagler Fellow
College of Medicine
Texas A&M University
College Station, Texas, USA
Prof. Michael A. Crawford, PhD, FRSB, FRSC, FRCPath
Visiting Professor, Department of Metabolism, Digestion and Reproduction
Chelsea & Westminster Hospital Campus
Imperial College London
United Kingdom
Prof. Jesmond Dalli, PhD, FHEA, FRSB, FBPhS
Professor of Molecular Pharmacology
Director, Lipid Mediator Unit
William Harvey Research Institute
Barts and The London School of Medicine and Dentistry
Queen Mary University of London
United Kingdom
Prof. Vincenzo Di Marzo, PhD
Canada Excellence Research Chair, Microbiome–Endocannabinoidome Axis in Metabolic Health
Université Laval, Quebec, Canada
Research Director, Institute of Biomolecular Chemistry
Consiglio Nazionale delle Ricerche (CNR), Italy
Prof. Jörg (Jürg) Gertsch, PhD
Professor, Institute of Biochemistry and Molecular Medicine
University of Bern
Switzerland
Prof. William S. Harris, PhD
Founder and President, Fatty Acid Research Institute
Professor of Medicine (Emeritus), Sanford School of Medicine
University of South Dakota
United States
Prof. Daniele Piomelli, PhD, MD (h.c.)
Distinguished Professor of Anatomy & Neurobiology, Biological Chemistry, and Pharmaceutical Sciences
Louise Turner Arnold Chair in the Neurosciences
Director, Center for the Study of Cannabis
University of California, Irvine
United States
Adjunct Professor
University of Vienna
Austria
Prof. Charles N. Serhan, PhD, DSc
Gelman Professor of Anaesthesia (Biochemistry & Molecular Pharmacology)
Director, Center for Experimental Therapeutics and Reperfusion Injury
Brigham and Women’s Hospital
Harvard Medical School
United States
Prof. Clemens von Schacky, MD
Chief Executive Officer, Omegametrix GmbH
Senior Researcher in Preventive Cardiology and Lipidomics
Munich, Germany
SIGN THE OPEN LETTER